Peter Holland-Fischer

Peter Holland-Fischer

Auto-generated profile, based on publicly available information

Peter Holland-Fischer

Department of Medicine V (Hepato and Gastroenterology), Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2011 in Gut
Verified
Journal Article
Closed access
PDF file
PHPeter Holland-Fischer
Peter Holland-Fischer
Henning GrønbækHenning Grønbæk
Henning Grønbæk
TSThomas Damgaard Sandahl
Thomas Damgaard Sandahl
SMSoren Kragh Moestrup
Soren Kragh Moestrup
OROliviero Riggio
Oliviero Riggio
HVHendrik Vilstrup
Hendrik Vilstrup
Introduction: Hepatic macrophages (Kupffer cells) undergo inflammatory activation during the development of portal hypertension in experimental cirrhosis; this activation may play a pathogenic role or be an epiphenomenon. Our objective was to study serum soluble CD163 (sCD163), a sensitive marker of macrophage activation, before and after reduction of portal venous pressure gradient by insertion of a transjugular intrahepatic portosystemic shunt (TIPS) in patients with cirrhosis. Methods: sCD163 was measured in 11 controls and 36 patients before and 1, 4 and 26 weeks after TIPS. We used lipopolysaccharide binding protein (LBP) levels as a marker of endotoxinaemia. Liver function and clinical status of the patients were assessed by galactose elimination capacity and Model for End Stage Liver Disease score. Results: The sCD163 concentration was more than threefold higher in the patients than in the controls (median 5.22 mg/l vs 1.45 mg/l, p<0.001). The sCD163 was linearly related to the portal venous pressure gradient (r 2 =0.24, p<0.001), also after adjustment for cirrhosis status. The sCD163 concentration was 12% higher in the hepatic than in the portal vein (p<0.02). The LBP level was 70% higher in the patients (52.2 vs 30.4 μg/l, p<0.001). During follow-up after TIPS, the sCD163 concentration did not change while LBP almost normalised. Conclusion: Kupffer cells were activated in patients with liver cirrhosis in parallel with their portal hypertension. The activation was not alleviated by the mechanical reduction of portal hypertension and the decreasing signs of endotoxinaemia. The findings suggest that Kupffer cell activation is a constitutive event that may play a pathogenic role for portal hypertension.

1 April 2009 in European Journal of Anaesthesiology
Verified
Journal Article
Closed access
PHPeter Holland-Fischer
Peter Holland-Fischer
JGJacob Greisen
Jacob Greisen
TGThorbjørn Grøfte
Thorbjørn Grøfte
TJTroels S Jensen
Troels S Jensen
PHPeter O Hansen
Peter O Hansen
HVHendrik Vilstrup
Hendrik Vilstrup
Tissue injury is accompanied by pain and results in increased energy expenditure, which may promote catabolism. The extent to which pain contributes to this sequence of events is not known. In a cross-over design, 10 healthy volunteers were examined on three occasions; first, during self-controlled nontraumatic electrical painful stimulus to the abdominal skin, maintaining an intensity of 8 on the visual analogue scale (0-10). Next, the electrical stimulus was reproduced during local analgesia and, finally, there was a control session without stimulus. Indirect calorimetry and blood and urine sampling was done in order to calculate energy expenditure and substrate utilization. During pain stimulus, energy expenditure increased acutely and reversibly by 62% (95% confidence interval, 43-83), which was abolished by local analgesia. Energy expenditure paralleled both heart rate and blood catecholamine levels. The energy expenditure increase was fuelled by all energy sources, with the largest increase in glucose utilization. The pain-related increase in energy expenditure was possibly mediated by adrenergic activity and was probably to a large extent due to increased muscle tone. These effects may be enhanced by cortical events related to the pain. The increase in glucose consumption favours catabolism. Our findings emphasize the clinical importance of pain management.

1 August 2010 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
PHPeter Holland-Fischer
Peter Holland-Fischer
MNMichael Festersen Nielsen
Michael Festersen Nielsen
HVHendrik Vilstrup
Hendrik Vilstrup
DTDennis Tønner-Nielsen
Dennis Tønner-Nielsen
AMAnette Mengel
Anette Mengel
Henning GrønbækHenning Grønbæk
Henning Grønbæk
Insertion of a transjugular intrahepatic porto-systemic shunt (TIPS) increases body cell mass (BCM) in patients with liver cirrhosis. The responsible mechanism is unidentified, but may involve changes in insulin sensitivity and glucose metabolism. Eleven patients with liver cirrhosis were examined before and 6 mo after a TIPS procedure with bioimpedance analyses, 2-h oral glucose tolerance tests, and two-step hyperinsulinemic euglycemic clamp with tracer-determined endogenous glucose production. After TIPS, BCM increased by 4.8 kg [confidence interval (CI): 2.7–7.3]. Fasting (f)-insulin increased from 123 ± 81 to 193 ± 124 pmol/l (P = 0.03), whereas f-glucose was unchanged (6.0 ± 0.8 vs. 6.2 ± 1.0 mmol/l). Glucose and insulin oral glucose tolerance test area under the curve increased by 14% (CI: 7–22%) and 53% (CI: 14–90%), respectively, P < 0.05. The C-peptide-to-insulin ratio decreased by 21% (CI: 8-35%, P = 0.01). Insulin sensitivity based on glucose infusion rate (4.69 ± 1.82 vs. 4.85 ± 2.37 mg·kg−1·min−1) and glucose tracer-based rate of disappearance were unchanged (5.01 ± 1.61 vs. 4.97 ± 2.13 mg·kg−1·min−1). Despite a further increase in peripheral hyperinsulinemia, f-endogenous glucose production did not change between study days (2.01 ± 0.42 vs. 2.42 ± 0.58 mg·kg−1·min−1) and was suppressed equally by insulin (1.1 ± 0.1 vs. 1.0 ± 0.1 mg·kg−1·min−1). Insulin clearance, growth hormone, cortisol, and glucagon levels were unchanged. BCM improvement did not correlate with the measured variables. After TIPS, BCM rose, despite enhanced hyperinsulinemia and aggravated glucose intolerance, but unchanged peripheral and hepatic insulin sensitivity. This apparent discrepancy may be ascribed to shunt-related decreased insulin exposure to the liver cells. However, the anabolic effect of TIPS seems not to be related to improvements in insulin sensitivity and remains mechanistically unexplained.

1 June 2009 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PHPeter Holland-Fischer
Peter Holland-Fischer
HVHendrik Vilstrup
Hendrik Vilstrup
JFJan Frystyk
Jan Frystyk
DNDennis Tønner Nielsen
Dennis Tønner Nielsen
AFAllan Flyvbjerg
Allan Flyvbjerg
Henning GrønbækHenning Grønbæk
Henning Grønbæk
Objective: Insertion of a transjugular intrahepatic porto-systemic shunt (TIPS) into patients with liver cirrhosis usually induces a gain in body cell mass. Changes in the IGF system in favor of anabolism may be involved. We, therefore measured blood concentrations of the components of the IGF system in cirrhosis patients before and after elective TIPS.Design and methods: The study comprised 17 patients and 11 healthy controls. Patients were examined before and 1, 4, 12, and 52 weeks after TIPS. Biochemical analyses of the IGF system were compared with changes in body composition (bioimpedance analysis), glucose and insulin, and metabolic liver function (galactose elimination capacity).Results: After TIPS, body cell mass rose by 3.2 kg (95% confidence interval (CI): 1.0–5.5) at 52 weeks, in correlation with baseline liver function (r2=0.22;P=0.03). Peripheral blood concentrations of total IGF1 and 2, bioactive IGF1, and the IGF-binding proteins (IGFBP-1, -2, and -3) remained unchanged throughout the study period. There was no change in fasting glucose, whereas fasting insulin rose by 40% (CI: 11–77%) and glucagon by 58% (CI: 11–132%) from baseline to 52 weeks after TIPS.Conclusion: Our data confirm that TIPS was associated with an increase in body cell mass in patients with liver cirrhosis, but without any change in the circulating IGF system. Thus, the results do not support the notion that effects on the circulating IGF system are involved in the anabolic effects of TIPS insertion.

31 August 2007 in Journal of Hepatology
Verified
Journal Article
Closed access
PDF file
PHPeter Holland-Fischer
Peter Holland-Fischer
PAPer Heden Andersen
Per Heden Andersen
SLSten Lund
Sten Lund
SPSteen Pedersen
Steen Pedersen
LVLars Vinter-Jensen
Lars Vinter-Jensen
HVHendrik Vilstrup
Hendrik Vilstrup